<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094247</url>
  </required_header>
  <id_info>
    <org_study_id>MMPUFA17</org_study_id>
    <nct_id>NCT03094247</nct_id>
  </id_info>
  <brief_title>Feeding Malnourished Children Different Types of Fatty Acids to Promote Neurocognitive Development</brief_title>
  <official_title>Improved Polyunsaturated Ready-to-use Therapeutic Food for Improved Neurocognitive Outcomes in Severe Acute Malnutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malawi College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An appropriate balance of omega-6 and omega-3 fatty acids is important for support of&#xD;
      neurocognitive development in healthy infants and toddlers. In young children recovering from&#xD;
      severe acute malnutrition (SAM), excess omega-6 intake depletes omega-3 fatty acid status.&#xD;
      This research will evaluate how novel ready-to-use therapeutic foods (RUTF) with balanced&#xD;
      fatty acids improve the metabolic and neurocognitive effects in young children in Malawi&#xD;
      recovering from SAM, yielding new knowledge that also has implications for development of&#xD;
      well-nourished children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Actual">March 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive outcome</measure>
    <time_frame>Time Frame: 4 to 7 months after nutritional outcome</time_frame>
    <description>Measured by score on the Malawian Developmental Assessment Test (MDAT). The scale is continuous and interval in nature, the range varies by population&#xD;
The scale title is &quot;Malawi Developmental Assessment Tool z-score&quot;&#xD;
The primary outcome is Global z-score, titled &quot;Global z-sore&quot;&#xD;
Secondary outcomes are 4 sub-domain z-scores are titled &quot;Gross motor z-score&quot;, &quot;Fine motor z-score&quot;, Language z-score&quot;, and &quot;Social z-score&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurocognitive outcome</measure>
    <time_frame>Time Frame: within 4 weeks after nutritional outcome</time_frame>
    <description>Defined by Willatts intention score adapted for field training, 3 problems to be tested. The scale is ordinal in nature, with higher values indicated better scores&#xD;
The scale title is &quot;Intention Score&quot;&#xD;
Problem 1 is scored 0 - 4&#xD;
Problem 2 is scored 0 - 4&#xD;
Problem 3 is scored 0 - 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional recovery</measure>
    <time_frame>Up to 12 weeks following enrollment</time_frame>
    <description>Defined by resolution of edema AND mid-upper arm circumference [MUAC] &gt;12.4cm, AND/OR a weight/height z-score [WHZ] &gt;-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attentional orienting speed</measure>
    <time_frame>4-7 months after nutritional after nutritional outcome</time_frame>
    <description>Measured by mean saccade latency to peripheral targets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Fortnightly follow up visits up to 12 weeks following enrollment</time_frame>
    <description>Measured by number of days diarrhea and/or rashes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of RUTF</measure>
    <time_frame>Fortnightly follow up visits up to 12 weeks following enrollment</time_frame>
    <description>Mother's report of if the child ate the food well. This is a yes or no question.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2897</enrollment>
  <condition>Severe Acute Malnutrition</condition>
  <arm_group>
    <arm_group_label>Conventional RUTF (S-RUTF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High oleic RUTF (HO-RUTF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA-supplemented HO-RUTF (D-HO-RUTF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>All patients with severe acute malnutrition will receive a course of amoxicillin.</description>
    <arm_group_label>Conventional RUTF (S-RUTF)</arm_group_label>
    <arm_group_label>DHA-supplemented HO-RUTF (D-HO-RUTF)</arm_group_label>
    <arm_group_label>High oleic RUTF (HO-RUTF)</arm_group_label>
    <other_name>Amoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HO-RUTF</intervention_name>
    <description>HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts</description>
    <arm_group_label>High oleic RUTF (HO-RUTF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-HO-RUTF</intervention_name>
    <description>D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts</description>
    <arm_group_label>DHA-supplemented HO-RUTF (D-HO-RUTF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>S-RUTF</intervention_name>
    <description>S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts</description>
    <arm_group_label>Conventional RUTF (S-RUTF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  6-59 months&#xD;
&#xD;
          -  An acceptable appetite defined by the ability to consume 30 grams RUTF within 20&#xD;
             minutes&#xD;
&#xD;
          -  Mid Upper Arm Circumference &lt;11.5 cm, weight-for-height z-score &lt; -3, or bilateral&#xD;
             pitting edema on the dorsum of the feet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any other ongoing study or supplementary feeding program&#xD;
&#xD;
          -  Children with a chronic medical condition, including cerebral palsy, static&#xD;
             encephalopathy, congenital heart disease, gastrointestinal disease, or peanut allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Manary, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Malawi College of Medicine</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malnutrition</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Polyunsaturated fatty acids</keyword>
  <keyword>Ready-to-use therapeutic foods</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Peanuts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Severe Acute Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

